Exobiosphere, a pioneering contract research organization based in Luxembourg, has successfully raised €2M in a seed funding round led by Expansion Ventures. The funding will accelerate the development of their Orbital High-Throughput Screener (OHTS), designed for drug discovery in space. This innovative platform aims to enhance disease modeling and therapy validation by leveraging microgravity, ultimately speeding up the drug development process and lowering costs. The company plans to expand its teams and customer base, marking significant growth and exploration prospects into the U.S. market.
Luxembourg-based Exobiosphere has raised €2M for its mission to redefine drug discovery in space using autonomous, standardised lab automation to improve efficacy.
Exobiosphere's Orbital High-Throughput Screener (OHTS) aims to lower drug development costs and time by utilizing microgravity for enhanced disease modeling and validation.
Collection
[
|
...
]